Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-13
2006-06-13
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S144000, C514S254090
Reexamination Certificate
active
07060703
ABSTRACT:
Compounds of formula (I)in which R1, R2, R3and R4have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.
REFERENCES:
patent: 6130239 (2000-10-01), Chen et al.
patent: 6258812 (2001-07-01), Bold et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 2004/0045044 (2004-03-01), Briesewitz et al.
patent: WO 96/40116 (1996-12-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 00/38519 (2000-07-01), None
patent: WO 00/73297 (2000-12-01), None
patent: WO 01/16130 (2001-03-01), None
patent: WO 01/25238 (2001-04-01), None
patent: WO 01/27080 (2001-04-01), None
patent: WO 01/27081 (2001-04-01), None
patent: WO 01/42243 (2001-06-01), None
patent: WO 01/60814 (2001-08-01), None
patent: WO 02/02551 (2002-01-01), None
patent: WO 02/16351 (2002-02-01), None
patent: WO 02/055517 (2002-07-01), None
Awada, A. et al, The pipeline of new anticancer agents for breast cancer treatment in 2003, Critical Reviews in Oncology/Hematology, vol. 48, pp. 45-63.
Nahta, R. et al., Novel pharmacological approaches in the treatment of breast cancer, Expert Opin. Investigational IDRugs, vol. 12(6), pp. 909-921.
Nahta, R. et al., “Growth Factor Receptors in Breast Cancer” Potential for Therapeutic Intervention, The Oncologist, vol. 8, pp. 5-17.
Barton, J. et al. Urology (Aug. 2001), vol. 58, Suppl. A2, pp. 155-155.
“Avastin-Tarceva Combo Provides ‘One-Two’ Punch Against Lung Cancer,” Science Daily (Jun. 7, 2004).
Goldman, B. “For Investigational Targeted Drugs, Combination Trials Pose Challenges,” J. National Cancer Institute (2003), vol. 95 (23), pp. 1744-1746.
Robinson, D. et al, “The protein kinase family of the human genome,” Oncogene (2000), vol. 19, pp. 5548-5557.
U.S. Food & Drug Administration, “FDA Statement on Iressa,” released Dec. 17, 2004, p. 1.
Abrams et al., Abstract: Su6668, a Broad Spectrum Angiogenesis Inhibitor, Is Active in Diverse Models of Tumor Growth and Metastasis, From the Proceedings of the AACR, vol. 42, Mar. 2001; Copyright 2001 by the American Association for Cancer Research; Online Publication Date: Feb. 27, 2001.
Abrams et al., “SU6668, a Broad Spectrum Angiogenesis Inhibitor is Active in Diverse Models of Tumor Growth and Metastasis”, Presented at AACR, 92nd Annual Meeting, Mar. 24-28, 2001, Ernest N. Morial Convention Center, New Orleans, LA.
Fiedler et al., “Abstract 1148:A Phase II Study With SU55416 in Patients With c-kit Positive AML”, Presented at ASCO 2001, American Society of Clinical Oncology, May 12-15, 2001, Moscone Center, San Francisco, California.
Fong et al., “SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types” Cancer Research, vol. 59, pp. 99-106 (Jan. 1, 1999).
Laird et al., “SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors1”, Cancer Research, vol. 60, pp. 4152-4160 (Aug. 1, 2000).
Levis et al., “A FLT3 tyrosine kinase inhibitor is selectively cytotoxis to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations”, Blood, vol. 98, No. 3, pp. 885-887 (Aug. 1, 2001).
O'Farrell et al., Abstract: “[497]SUGEN Compounds SU5416 and SU11248 Inhibit Flt3 Activity:Therapeutic Applications in AML.”, Presented at American Society of Hematology Meeting, Dec. 7-11, 2001, Orlando, Florida (1 sheet).
Pandey et al., “Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family”, J. Med. Chem, vol. 45, pp. 3772-3793 (2002).
Shaheen et al., “Tyrosine Kinase Inhibition of Multiple Angiogenic Growth Factor Receptors Improves Survival in Mice Bearing Colon Cancer Liver Metastases by Inhibition of Endothelial Cell Survival Mechanisms1”, Cancer Research, vol. 61, pp. 1464-1468 (Feb. 15, 2001).
Sun et al., “Design, Synthesis, and Evaluations of Substituted 3-[3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases”, J. Med. Chem., vol. 42, pp. 5120-5130 (1999).
Sun et al., Identification of Substituted 3-[4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases J. Med. Chem., vol. 43, pp. 2655-2663 (2000).
Sun et al., “Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases”, J. Med. Chem., vol. 41, pp. 2588-2603 (1998).
Traxler et al., “Protein tyrosine kinase Inhibitors in cancer treatment”, Exp. Opin. Ther. Patents, vol. 7, No. 6, pp. 571-588 (1997).
Wild et al., Abstract: “SU5416 and SU6668 Inhibit Tyrosine Kinase Mediated Survival Signals and Induce Apoptosis in Myeloid Leukemia Cells”, From the Proceedings of the AACR, vol. 42, Mar. 2001; Copyright 2001 by the American Association for Cancer Research; Online Publication Date: Feb. 27, 2001 (1 sheet).
Yee et al., Abstract: “SU5416 Inhibits wild-type and activated mutant FLT3 signaling in leukemia cells”, Copyright 2001 American Association for Cancer Research; Proceedings of the AACR-NC1-EORTC International Conference; Published as a Supplement to Clinical Cancer Research, vol. 7, No. 11, Nov. 2001 (1 sheet).
Yee et al., “SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT 3 receptor tyrosine kinase”, Blood, vol. 100, No. 8, pp. 2941-2949 (Oct. 15, 2002).
U.S. Appl. No. 11/008,746, filed Dec. 9, 2004, Briesewitz.
Aiello et al., “Suppression of retinal neovascularizationin vivoby inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins”, Proc. Natl. Acad. Sci USA, vol. 92, pp. 10457-10461, Nov. 1995.
Drevs et al., “Effects of PTK787/ZK 222584, a Specific Inhibitor of Fascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model”, Cancer Research 60, pp. 4819-4824 (Sep. 1, 2000).
Mendel et al., “In VivoAntitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship”, Clinical Cancer Research, vol. 9, pp. 327-337 (Jan. 2003).
Wood, “Inhibition of Vascular Endothelial Growth Factor (VEGF) as a Novel Approach for Cancer Therapy”, Medicina (Buenos Aires) 60 (Supl. II), pp. 41-47 (2000).
Zwick et al., “Receptor tyrosine kinase signalling as a target for cancer intervention strategies”, Endocrine-Related Cancer, vol. 8, pp. 161-173 (2001).
Briesewitz Roger
Griffin John H.
Wray Jonathan W.
Cohen Joyce G.
Coppins Janet L.
Hagenah Jeffery
Saeed Kamal A.
Saxon Roberta P.
LandOfFree
Indolinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3614864